{
    "clinical_study": {
        "@rank": "16804", 
        "arm_group": [
            {
                "arm_group_label": "FDC first, fasted", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition"
            }, 
            {
                "arm_group_label": "Single tablets first, fasted", 
                "arm_group_type": "Experimental", 
                "description": "single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition"
            }, 
            {
                "arm_group_label": "FDC first, fed", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition"
            }, 
            {
                "arm_group_label": "Single tablets first, fed", 
                "arm_group_type": "Experimental", 
                "description": "single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose\n      combination (FDC) tablet containing linagliptin and metformin extended release compared to\n      the free combination of linagliptin and metformin extended release."
        }, 
        "brief_title": "Bioequivalence of a Low, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Healthy male or female subjects\n\n        Exclusion criteria:\n\n        - Any relevant deviation from healthy condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121509", 
            "org_study_id": "1288.10", 
            "secondary_id": "2013-005143-85"
        }, 
        "intervention": [
            {
                "arm_group_label": "FDC first, fasted", 
                "description": "1 x Linagliptin tablet", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fed", 
                "description": "1 x Linagliptin tablet", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fed", 
                "description": "2 x Linagliptin/Metformin ER FDC tablet", 
                "intervention_name": "Linagliptin/Metformin ER FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC first, fed", 
                "description": "1 x Linagliptin tablet", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC first, fed", 
                "description": "2 x Linagliptin/Metformin ER FDC tablet", 
                "intervention_name": "Linagliptin/Metformin ER FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC first, fed", 
                "description": "3 x Metformin ER tablets", 
                "intervention_name": "Metformin ER", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fed", 
                "description": "3 x Metformin ER tablets", 
                "intervention_name": "Metformin ER", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC first, fasted", 
                "description": "3 x Metformin ER tablets", 
                "intervention_name": "Metformin ER", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fasted", 
                "description": "2 x Linagliptin/Metformin ER FDC tablet", 
                "intervention_name": "Linagliptin/Metformin ER FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fasted", 
                "description": "1 x Linagliptin tablet", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC first, fasted", 
                "description": "2 x Linagliptin/Metformin ER FDC tablet", 
                "intervention_name": "Linagliptin/Metformin ER FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single tablets first, fasted", 
                "description": "3 x Metformin ER tablets", 
                "intervention_name": "Metformin ER", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "BI 1356", 
                "Metformin"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1288.10.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/750 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Maximum measured concentration of linagliptin in plasma (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Cmax of metformin in plasma", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "AUC0-inf of metformin in plasma", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}